Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) today announced it will report financial results and operational highlights for the second quarter of 2026 before hosting a conference call and webcast at 8:30 a.m. ET on August 10, 2026. The company, a fully-integrated commercial-stage biotechnology firm focused on central nervous system (CNS) and immunology treatments, will discuss recent progress including its flagship medicine TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years.
The conference call will provide a platform for management to elaborate on the quarter's performance and pipeline advancements. A replay of the webcast will be available in the Investors section of the company's website following the event. For full details, refer to the press release at https://ibn.fm/A9CfR.
Tonix's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra®. The company is also exploring TONMYA's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, its CNS pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare disease. On the immunology front, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
These developments underscore Tonix's commitment to addressing high unmet medical needs in CNS and immunology. The second-quarter results will give investors insight into the company's financial health and operational milestones as it continues to commercialize TONMYA and advance its pipeline. Stay updated with the latest news on TNXP at the company's newsroom: https://ibn.fm/TNXP.
Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
